METRONIDAZOLE IV DRUG USE INVESTIGATION
Conditions: Anaerobic Infection, Infectious Enterocolitis, Amebic Dysentery
Sponsor: Pfizer

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Anaemetro I.V. Infusion 500 mg Drug Use Investigation
NON-INTERVENTIONAL (NI) STUDY PROTOCOL

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 1 of 29
STUDY INFORMATION
Title
Anaemetro I.V. Infusion 500 mg
Drug Use Investigation
Protocol number
A6831007
Protocol version identifier
Amended1
Date of last version of protocol
01 April 2015
Active substance
Metronidazole
Medicinal product
Anaemetro I.V. Infusion 500 mg
Research question and objectives
This study will be conducted to investigate
the safety and effectiveness of Anaemetro
I.V. Infusion 500 mg in daily clinical 
practice. Additionally, it is intended to 
assess the following:
! Adverse reactions unexpected from
precautions, and
! Occurrence of adverse reactions under 
actual clinical settings
"Central nervous system disorder" also will
be confirmed for the tendency of adverse 
reactions under actual clinical settings.
Author
Post Marketing Study Strategy and 
Management
PMS Planning & Operation Group 1
PPD

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 2 of 29
TABLE OF CONTENTS
TABLE OF CONTENTS.................................................................................................................2
1. LIST OF ABBREVIATIONS......................................................................................................5
2. RESPONSIBLE PARTIES..........................................................................................................6
3. AMENDMENTS AND UPDATES.............................................................................................7
4. MILESTONES.............................................................................................................................7
5. RATIONALE AND BACKGROUND........................................................................................7
6. RESEARCH QUESTION AND OBJECTIVES .........................................................................8
6.1. Safety specifications........................................................................................................8
7. RESEARCH METHODS ............................................................................................................8
7.1. Study design ....................................................................................................................8
7.2. Setting..............................................................................................................................8
7.2.1. Inclusion criteria .................................................................................................9
7.2.2. Exclusion criteria................................................................................................9
7.2.3. Sites for this study ..............................................................................................9
7.2.4. Planned investigation period...............................................................................9
7.2.5. Study methods ....................................................................................................9
7.2.6. Observation period..............................................................................................9
7.3. Variables..........................................................................................................................9
7.3.1. Background.......................................................................................................10
7.3.2. Targeted drug use record ..................................................................................11
7.3.3. Concomitant therapy.........................................................................................11
7.3.4. Tests..................................................................................................................11
7.3.5. End-of-study (discontinuation) record..............................................................12
7.3.6. Effectiveness evaluation...................................................................................13
7.3.7. Adverse events..................................................................................................14
7.3.8. Major investigation items .................................................................................15
7.4. Data sources ..................................................................................................................15
7.5. Study size ......................................................................................................................15
7.5.1. Planned sample size..........................................................................................15
7.5.2. Rationale for sample size..................................................................................15
7.6. Data management..........................................................................................................16

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 3 of 29
7.6.1. Data collection method.....................................................................................16
7.6.2. Patient registration............................................................................................16
7.6.3. Reminders concerning completion, revision, and submission of case 
report form....................................................................................................17
7.7. Data analysis .................................................................................................................17
7.8. Quality control...............................................................................................................18
7.9. Limitations of the research methods .............................................................................18
7.10. Other aspects ...............................................................................................................19
8. PROTECTION OF HUMAN SUBJECTS ................................................................................19
8.1. Patient information and consent....................................................................................19
8.2. Patient withdrawal.........................................................................................................19
8.3. Institutional review board (IRB)/independent ethics committee (IEC) ........................19
8.4. Ethical conduct of the study..........................................................................................19
9. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE 
REACTIONS .......................................................................................................................19
9.1. Requirements.................................................................................................................20
9.2. Reporting period............................................................................................................21
9.3. Causality assessment.....................................................................................................21
9.4. Definitions of safety events...........................................................................................21
9.4.1. Adverse events..................................................................................................21
9.4.2. Serious adverse events......................................................................................23
9.4.3. Scenarios necessitating reporting to Pfizer Safety within 24 hours .................24
9.5. Single reference safety document..................................................................................27
10. PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS..............27
11. ORGANIZATIONAL SYSTEM FOR STUDY IMPLEMENTATION.................................27
12. NAME, ADDRESS AND OUTSOURCED OPERATIONS OF THE PERSON WHO 
WAS CONTRACTED WITH THE OPERATIONS...........................................................27
13. ADDITIONAL MEASURES THAT MAY BE IMPLEMENTED BASED ON THE 
STUDY RESULTS AND CRITERIA FOR DETERMINATION OF THE 
INITIATION ........................................................................................................................28
14. SCHEDULED TIMING OF MILESTONES AND THEIR RATIONALES FOR 
REPORTING OF STUDY IMPLEMENTATION STATUS AND EVALUATION
OF OBTAINED RESULTS TO THE PMDA .....................................................................28
15. OTHER NECESSARY MATTERS ........................................................................................28

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 4 of 29
16. CONTACT INFORMATION..................................................................................................29
16.1. Contact information for the contents of the study.......................................................29
17. REFERENCES ........................................................................................................................29
18. LIST OF TABLES...................................................................................................................29
19. LIST OF FIGURES .................................................................................................................29
20. LIST OF STAND ALONE DOCUMENTS ............................................................................29
21. ADDITIONAL INFORMATION............................................................................................29

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 5 of 29
1. LIST OF ABBREVIATIONS
Acronym
Tittle
AE
adverse event
CRF
case report form
CRP
C-reactive protein 
EDP
exposure during pregnancy
ID
identification
IEC
independent ethics committee
IRB
institutional review board
MHLW
Ministry of Health, Labour and Welfare
MIC
minimum inhibitory concentration 
N/A
not applicable
NIS
non-interventional study  
PID
pelvic inflammatory disease and other related diseases
PMDA
Pharmaceuticals and Medical Devices Agency
RMP
Risk Management Plan
SAE
serious adverse event
SAP
statistical analysis plan
SRSD
Single Reference Safety Document
WBC
white blood cell

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 6 of 29
2. RESPONSIBLE PARTIES
The Japan Good Post marketing Study Practice officer
Principal Investigator(s) of the Protocol
N/A

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 7 of 29
3. AMENDMENTS AND UPDATES
Amendment 
number
Date
Substantial or 
administrative 
amendment
Protocol 
section(s) 
changed
Summary
of amendment(s)
Reason
Amended1
10 January
2017
Other
amendment(s)
4.
7.2.4.
Section 4.
Change in the end of 
data collection from 
"March 2017" to "May 
2017"
Section 7.2.4.
Change in investigation
period from "April 
2015 to March 2017" to 
"April 2015 to May 
2017" and change in 
registration period from 
"April 2015 to January
2017" to "April 2015 to 
March 2017"
It was decided to 
extend 
investigation 
period and
registration period
another 2 months,
since it is possible 
that the target 
number of 
patients in the 
safety analysis set
would not be
reached by the 
end of the 
registration period 
planned in this 
study.
4. MILESTONES
Milestone
Planned date
Start of data collection
April 2015
End of data collection
May 2017
Final study report
To be decided
5. RATIONALE AND BACKGROUND
Anaemetro I.V. Infusion 500 mg (hereinafter referred to as "this drug") is an injection of 
metronidazole, which has been used for a long time in Japan. Metronidazole has a strong 
antibacterial or antiprotozoan activity against obligate anaerobes or protozoa respectively; for 
which, it is recommended in various domestic and overseas guidelines and textbooks, and highly 
regarded as a therapeutic method for anaerobic infection.
Anaerobic infection developed in patients with severe underlying diseases frequently becomes
more refractory or serious due to the patients' susceptibility to infection. Patients in such a 
serious condition often have difficulties taking oral medications, and thus, metronidazole 
injection would be beneficial.
Such background warrants the great clinical significance to make metronidazole injection 
clinically available; for which, Pfizer obtained the approval to manufacture and market this drug
in Japan in July 2014.

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 8 of 29
The drug use investigation of Anaemetro I.V. Infusion 500 mg (hereinafter referred to as "this
study") shall be conducted to collect information regarding the occurrence by type of adverse 
reactions associated with this drug in daily clinical practice, and information regarding the 
quality, effectiveness, and safety of this drug. The information collected from this study shall be 
used to provide proper use information and prepare documents for the application of re-
examination.
This study shall be conducted in strict compliance with the "MHLW Ordinance on the Standard 
for Post-Marketing Studies and Clinical Trials of Medical Products" (MHLW Ordinance No. 171 
dated December 20, 2004).
Data obtained from the patients registered in this study will be reported to the MHLW pursuant 
to the Pharmaceutical and Medical Device Act; pertinent to which, data may be publicly posted 
in MHLW's "Pharmaceuticals and Medical Devices Safety Information" and "Pharmaceuticals 
and Medical Devices Information Website (http://www.info.pmda.go.jp) as a listing of patients, 
which will present the names of drugs, adverse reactions, sex, age (increment of 10 years), and 
other relevant information. Furthermore, data collected may also be disclosed if the MHLW is 
required to disclose such information in accordance with the "Act on Access to Information Held 
by Administrative Organs" (Law No. 42 dated May 14, 1999) provided that in no event will the 
names of physicians, medical institutions, and other personal information be subject to such 
disclosure, nor will it be posted or disclosed in any form or shape.
6. RESEARCH QUESTION AND OBJECTIVES
This study will be conducted to investigate the safety and effectiveness of this drug in daily 
clinical practice. Additionally, it is intended to assess the following:

Adverse reactions unexpected from precautions, and

Occurrence of adverse reactions under actual clinical settings
"Central nervous system disorder" also will be confirmed for the tendency of adverse reactions 
under actual clinical settings.
6.1. Safety specifications
[Important Identified Risks] Central nervous system disorder
7. RESEARCH METHODS
7.1. Study design
This study is a multicenter open-label study conducted in patients receiving this drug; for which, 
case report forms (CRFs) will be recorded based on data presented in medical records obtained 
in daily clinical practice.
7.2. Setting
Patients who satisfy all of the inclusion criteria are subject to this study.

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 9 of 29
7.2.1. Inclusion criteria
Patients who have not used metronidazole (injection) in the past, and have been administered this 
drug for treatment of anaerobic infection, infectious enterocolitis, or amebic dysentery. Patients 
who have used metronidazole (oral agent and vaginal tablet) in the past are eligible, and should 
not be excluded from this study.
7.2.2. Exclusion criteria
No exclusion criteria are set out in this study.
7.2.3. Sites for this study
The sites with presence of doctors specialized in the target therapeutic area primarily in the 
following departments, at which, this drug can be prescribed:
Gastroenterology, gastroenterological surgery, respiratory medicine, gynecology, and infection
7.2.4. Planned investigation period
Investigation period: April 2015 to May 2017
Registration period: April 2015 to March 2017
(Even before the end of the registration period, registration will be discontinued if the target 
number of patients is reached)
7.2.5. Study methods
This study will be a prospective study, in which, patients will be registered with central 
registration system until the target number of patients meeting the registration criteria are 
reached.
7.2.6. Observation period
The observation period shall start on the day the treatment with this drug begins and end on the 
day the treatment is completed; however, it shall be cut off at Week 8 after the initiation of 
treatment (Day 56 counting from Day 1 as the day the treatment begins) if the treatment is 
prolonged.
7.3. Variables
This study will be conducted in accordance with the following variables/schedule of observation 
(Table 1).

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 10 of 29
Table 1. Variables/schedule of observation
Timing
Variables
Initiation of 
treatment
Observation period
Completion of 
observation period
Background
ID number
●
Sex
●
Age (on the date of treatment 
initiation)
●
Height/body weight
●
Hospitalization status 
(inpatient/outpatient)
●
Targeted disease
●
Medical history
●
Targeted drug use record
●
Concomitant therapy (Drug therapy)
●
Vital sign/laboratory tests (body temperature, 
WBC count, and CRP)
●
Microbiological test
●
Effectiveness evaluation
●
End-of-study (discontinuation) record
●
Adverse events
●
●: Data items to complete
7.3.1. Background
Input the information at the initiation of treatment with this drug.
[1] ID number
[2] Sex
[3] Age
[4] Height
[5] Body weight
[6] Hospitalization status (inpatient/outpatient)
[7] Targeted disease (infection for which this drug is used)

Name of disease

Severity
[8] Medical history (information except for targeted disease)

Presence/absence of hepatic functional impairment or renal functional impairment

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 11 of 29

Name of disease or syndrome other than the above, as well as the history or the 
complication
[9]
History of surgery if the targeted disease is a secondary infection due to surgery

Disease name for which the surgical operation is performed

Date of surgery
7.3.2. Targeted drug use record
The following will be recorded for the targeted drug.
[1] Daily dose
[2] Number of doses per day
[3] Treatment period (start date/end date)
[4] Reason for change of dose
7.3.3. Concomitant therapy
7.3.3.1. Drug therapy
Medications used for the infection
The following information will be recorded for medications used for the infection during a 
period from 14 days before the initiation of treatment with this drug to the completion date of 
observation period.
[1] Drug name (product name)
[2] Route of administration
[3] Date of treatment initiation
[4] Presence/absence of concomitant use at the time the treatment with this drug begins
7.3.4. Tests
7.3.4.1. Vital sign/laboratory tests
Vital sign/laboratory tests
Record the following vital sign/laboratory parameters before the initiation of treatment with this 
drug, during the observation period, and at the completion of observation period.
[Vital sign/laboratory parameters] Body temperature, WBC count, and CRP

Test date 

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 12 of 29

Test results
7.3.4.2. Other tests
Microbiological test
Record the pathogen for which this drug is used, and the expected results of test on the causative 
organism. Record the following information before the initiation of treatment with this drug, 
during the observation period, and at the completion of observation period.
[1] Specimen
[2] Pathogen, and the name of causative bacterial strain
[3] Date of sampling
[4] Test method
[5] Pathogen result (Semi-quantitative) (-, +, ++, +++, Unknown)
[6] MIC of this drug
[7] Presence/absence of ameba protozoa
7.3.5. End-of-study (discontinuation) record
If the observation is completed or discontinued before the end of the longest observation period 
(8 weeks), the reason should be recorded.
If an adverse event (AE) is selected for the reason, the information in details should be recorded 
in the AE column.
[Reason for completion]

Cured (effective)
[Reason for discontinuation]

Insufficient clinical response

AE

Hospital transfer

Others
Presence/absence of pregnancy on the completion date of the observation period (if present, the 
delivery date or expected date of delivery)

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 13 of 29
7.3.6. Effectiveness evaluation
(1) Clinical response
The clinical response of this drug should be evaluated comprehensively at the completion of the 
observation period, and the results should be recorded.
If this drug is administered continuously for more than 8 weeks, the clinical response should be 
evaluated comprehensively at Week 8.

Effective

Not effective

Indeterminate (the reason should be recorded.)
The assessment criteria shall be as follows:
Table 2. Assessment criteria for [anaerobic infection] / [infectious enterocolitis (including 
pseudomembranous colitis)]
Assessment
Definition
Effective
Clinical symptoms accompanying the infection observed at the initiation of 
treatment with this drug has improved at the time of assessment, and treatment 
with other antibacterial drugs after the time of assessment is determined not 
necessary.
Not effective
"Effective" criteria are not met.
Indeterminate
Clinical response is difficult to evaluate.
Table 3. Assessment criteria for [amebic dysentery]
Assessment
Definition
Effective
Clinical symptoms accompanying the infection observed at the initiation of 
treatment with this drug has improved at the time of assessment, and treatment 
with other antibacterial drugs other than antiamebic agents (paromomycin, etc.) 
after the time of assessment is determined not necessary.
Not effective
"Effective" criteria are not met.
Indeterminate
Clinical response is difficult to evaluate.
Any clinically problematic finding compared to the initiation of treatment should be recorded in 
details in the AE column.
(2) Rationale for clinical response assessment
The rationale for the clinical response assessment ("Effective" or "Not effective"), on the disease 
for which this drug is used, should be recorded.
[Anaerobic infection]

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 14 of 29
General clinical findings, body temperature, WBC count, CRP level, imaging, and others
[Infectious enterocolitis (including pseudomembranous colitis)]
General clinical findings, Clostridium difficile TOXIN test, frequency of diarrhea, body 
temperature, abdominal pain, and others
[Amebic dysentery]
General clinical findings, ameba test, frequency of diarrhea, body temperature, abdominal pain, 
and others
(3) Microbiological response assessment
Microbiological response at the completion of observation period compared to prior to the 
initiation of treatment with this drug should be assessed, and the results should be recorded.
Table 4. Assessment criteria for microbiological response
Assessment
Definition
Eradication
Pathogen is not detected in the specimen appropriately collected following 
administration of this drug.
Presumed 
eradication
Pathogen is presumed eradicated if the treatment improves or resolves the 
clinical symptoms, and a specimen suitable for the test is no longer available 
in the original infection focus.
Partial 
eradication
Pathogen is partially detected in the specimen appropriately collected 
following administration of this drug.
Persistence
No improvement of clinical symptoms is confirmed, and the pathogen is 
detected in the infection focus.
Indeterminate
A microbiological test was conducted, but no pathogen could be isolated or 
estimated.
Or a microbiological test was not conducted due to various reasons.
7.3.7. Adverse events
After confirming the occurrence of AEs from the initiation of treatment with this drug to the 
completion date of observation period, the following information will be recorded. Upon 
occurrence of any AE, the investigator should take appropriate measures, and promptly report to 
Pfizer Japan Inc. (hereinafter "Sponsor"), and if causal relationship with this drug cannot be 
ruled out, the investigator should follow up the event until the AE or its sequelae are resolved or 
stabilized at the level acceptable to the investigator and Sponsor.
Moreover, a study should be separately conducted in detail on patients in whom a serious 
adverse reaction, or an adverse reaction not described in the package insert occurred if it is 
determined necessary by Sponsor.
[1] Presence/absence of AE
[2] Name of AE

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 15 of 29
[3] Presence/absence of AE concerning central nervous system disorder
[4] Date of occurrence
[5] Intervention
[6] Seriousness
[7] Outcome
[8] Causal relationship
[If the AE is associated with abnormal change in laboratory values, i.e., clinical laboratory tests, 
the following information should also be recorded.]
[1] Laboratory parameter
[2] Site reference value
[3] Unit
[4] Date measured
[5] Results
Detailed study on adverse reactions concerning central nervous system disorder
Completion of detailed CRF should be separately requested on central nervous system disorder 
that occurred in patients subject to this study if it is determined necessary by Sponsor.
7.3.8. Major investigation items
N/A
7.4. Data sources 
In this study, the investigator extracts the necessary information from the medical record in 
accordance with the protocol.
7.5. Study size
7.5.1. Planned sample size
100 patients (for safety analysis)
7.5.2. Rationale for sample size
The target sample size was set to be 100 patients, which should enable to detect, at 95% 
probability, an adverse reaction of which the true incidence rate is 3% in reference to adverse 
reaction of the least incidence in a clinical study of this drug (Study A6831005). This sample 
size should enable to confirm whether the types and incidence of adverse reaction related to this 

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 16 of 29
drug used for diseases other than intra-abdominal infection, and pelvic inflammatory disease and 
other related diseases (hereinafter referred to as "PID") that were targeted in the clinical study
would be similar to those occurred in Study A6831005.
Events specified as important identified risks or important potential risks in the Risk 
Management Plan (RMP) may not have a high incidence, and thus, may not detect sufficient
information only from the drug use investigation; nonetheless, such an event collected in the 
drug use investigation should be investigated within the framework of the drug use investigation. 
Moreover, these events should also be monitored through the routine pharmacovigilance 
activities.
The sample size of 100 patients are expected to enable accumulating data on the number of 
patients at the level similar to the clinical study in terms of clinical response rate of this drug for 
diseases other than intra-abdominal infection and PID that were targeted in the clinical study and 
also in terms of clinical response rate in subgroup analysis by each major indication; which 
should enable verification whether the effectiveness under actual clinical settings is similar to the 
results of the clinical study.
7.6. Data management
7.6.1. Data collection method
The data for this study will be collected using a specific CRF provided by Sponsor. The 
investigator will complete the CRFs promptly after the completion of observation period and 
submit them to the Sponsor.
7.6.2. Patient registration
7.6.2.1. Procedure of patient registration
(1) Registration
The following registration items should be completed in the registration forms for patients 
with anaerobic infection, infectious enterocolitis, or amebic dysentery who are given 
Anaemetro I.V. Infusion 500 mg and meet the registration requirements; patients should be 
registered via FAX at the registration center until the target number of patients is registered. 
The patients should be registered before Day 8 of treatment counting from the initiation of 
treatment with Anaemetro I.V. Infusion 500 mg as Day 1.
1) Registration criteria
Patients who have not used Anaemetro I.V. Infusion 500 mg before the initiation of 
treatment with this drug
2) Registration items
Patient ID number, sex, age on the date of treatment initiation, date of treatment initiation
with this drug, eligibility to registration criteria, and disease targeted in this study
(disease for which this drug is used)

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 17 of 29
(2) Exclusion from the registration
Patients found to not meet the registration criteria after the registration form is received at 
the registration center will be excluded from the registration.
7.6.3. Reminders concerning completion, revision, and submission of case report form
7.6.3.1. Completion
The investigator shall, upon confirming the study items, complete the CRF based on medical 
charts and other medical records such as relevant test results, using a pen, ballpoint pen, or other 
inerasable means.
7.6.3.2. Revision
Upon receiving Sponsor's inquiry on the contents of the CRF (query forms), the investigator will 
again confirm the contents of medical records described earlier, and as required, correct relevant 
sections and resubmit the form. Corrections in the CRF should be struck out with a double line 
(=) with a "correction seal" on the double line; the double line should be drawn so that the 
original contents prior to correction are legible.
7.6.3.3. Submission
CRFs should be submitted promptly upon completion in accordance with the procedures set out 
by Sponsor.
7.7. Data analysis
The details of methods of analysis on data collected in this study shall be described in the 
statistical analysis plan (SAP) to be separately prepared.

Definition of analysis set
The safety analysis set shall include patients for whom the registration in this study and 
administration of this drug have been confirmed.
Two analysis sets, which are clinically-evaluable analysis set and microbiological analysis 
set shall be defined as the effectiveness analysis set. The clinically-evaluable analysis set 
includes patients who were confirmed to conduct the clinical evaluation in the safety 
analysis set. The microbiological analysis set includes patients for whom microbiological 
response was assessed in the clinically-evaluable analysis set.

Methods of analysis
[Patient Registration Center]
FAX: 0120–771–297 (Available 24 hours a day)

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 18 of 29
(1)Analysis for safety evaluation
The incidence of adverse reactions will be calculated for each event. Also, the factors 
affecting the occurrence of adverse reaction will be evaluated as necessary.
(2)Analysis for effectiveness evaluation
The clinical response rate in terms of the clinical effectiveness will be set as the primary 
effectiveness endpoint. The number of patients with "effective" and its proportion 
(clinical response rate) among the clinically-evaluable analysis set, and its 95% 
confidence interval will be calculated. The number of patients with eradication or 
presumed eradication, and its proportion (eradication rate) among the microbiological 
analysis set, and its 95% confidence interval will be calculated. The clinical response
rate for each disease and its 95% confidence interval, and the eradication rate and its 
95% confidence interval will be calculated. Also, an exploratory analysis on the factors 
affecting the effectiveness will be performed as necessary.
Clinical response rate 
(%) = 
Number of patients with "effective"
×100
Number of clinically-evaluable patients excluding 
"indeterminate"
Eradication rate (%) = 
Number of patients with "eradication" + "presumed 
eradication"
×100
Number of patients in the microbiological analysis 
set excluding "indeterminate"
Detailed methodology for summary and statistical analyses of data collected in this study will be 
documented in a SAP, which will be dated, filed and maintained by the Sponsor. The SAP may 
modify the plans outlined in the protocol; any major modifications of primary endpoint 
definitions or their analyses would be reflected in a protocol amendment.
7.8. Quality control
The site staff will explain the contents of the protocol, etc. to the investigator prior to the 
implementation of this study and ask the investigator to prepare a CRF based on medical charts.
7.9. Limitations of the research methods
The following matters are considered for this study:
1)
Since no control group is set in the study, there is a limit to the judgment on whether or not a 
risk of developing AEs and adverse reactions increases due to the administration of the study 
drug.
2)
The consideration for confounding factors may not be adequate because the background 
information may not be sufficiently obtained.

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 19 of 29
3)
Since this is a study that collects the information described in medical charts, the set data 
may not be collected or there may be missing information.
7.10. Other aspects
N/A
8. PROTECTION OF HUMAN SUBJECTS
8.1. Patient information and consent
All parties will ensure protection of patient personal data and will not include patient names on 
any sponsor forms, reports, publications, or in any other disclosures, except where required by 
laws. In case of data transfer, Pfizer will maintain high standards of confidentiality and 
protection of patient personal data.
In this study, the information will be collected by transcribing medical chart information 
described in routine medical practice. In doing so, the informed consent will not be required
because the information collected from medical charts is anonymized and does not contain any 
information that identifies individual patients.
8.2. Patient withdrawal
Patients may withdraw from the study at any time at their own request, or they may be 
withdrawn at any time at the discretion of the investigator or Sponsor for safety, behavioral, or 
administrative reasons.  In any circumstance, every effort should be made to document subject
outcome, if possible.  The investigator should inquire about the reason for withdrawal and 
follow-up with the subject regarding any unresolved AEs.  
8.3. Institutional review board (IRB)/independent ethics committee (IEC)
In this study, the review by the IRB/IEC is not essential.
8.4. Ethical conduct of the study
This study is excluded from the patient since it includes the scope of application of the "MHLW 
Ordinance on the Standard for Post-Marketing Studies and Clinical Trials of Medical Products" 
(MHLW Ordinance No. 171 dated December 20, 2004).
9. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE 
REACTIONS
The handling of each event in the case where the investigator becomes aware of any event 
concerning the safety information should be prescribed as follows:
For an event that needs to be reported to the Sponsor within 24 hours, the investigator must 
report it using the designated "Non-Interventional Study AE Report Form" (hereinafter referred 
to as "NIS AE Report Form").

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 20 of 29
At the initiation of study, the site staff should request the investigator to report events that need 
to be reported within 24 hours of awareness, and visit the investigator periodically during the 
study period to request for reporting. 
The NIS AE Report Form will be handled as part of the CRF.
9.1. Requirements
The table below summarizes the requirements for recording safety events on the CRF and for 
reporting safety events on the NIS AE Report Form to Pfizer Safety. These requirements are
delineated for three types of events: (1) serious adverse events (SAEs); (2) non-serious AEs (as 
applicable); and (3) scenarios involving drug exposure, including exposure during pregnancy
(EDP), exposure during breast feeding, medication error, overdose, misuse, extravasation, lack 
of efficacy, and occupational exposure. These events are defined in the section "Definitions of 
safety events".  
Safety event
Recorded on the CRF
Reported on the NIS AE Report 
Form to Pfizer Safety within 24 
hours of awareness
SAE
All
All
Non-serious AE
All
None
Scenarios involving exposure to this 
drug, including EDP, exposure during 
breast feeding, medication error, 
overdose, misuse, extravasation, lack 
of efficacy, and occupational exposure
All (regardless of whether associated 
with an AE), except occupational 
exposure
All (regardless of whether 
associated with an AE)
For each AE, the investigator must pursue and obtain information adequate both to determine the 
outcome of the AE and to assess whether it meets the criteria for classification as a SAE (see 
section "Serious adverse events" below) 
Safety events must be reported to Pfizer within 24 hours of awareness of the event by the 
investigator as described in the table above regardless of whether the event is determined by 
the investigator to be related to a drug under study. In particular, if the SAE is fatal or life-
threatening, notification to Pfizer must be made immediately, irrespective of the extent of 
available event information. This timeframe also applies to additional new (follow-up) 
information on previously forwarded safety event reports. In the rare situation that the 
investigator does not become immediately aware of the occurrence of a safety event, the 
investigator must report the event within 24 hours after learning of it and document the time of 
his/her first awareness of the events.
For those safety events that are considered serious or that are identified in the far right column of 
the table above that are reportable to Pfizer within 24 hours of awareness, the investigator is 
obligated to pursue and to provide any additional information to Pfizer in accordance with this 
24-hour timeframe. In addition, an investigator may be requested by Pfizer to obtain specific 
follow-up information in an expedited fashion. This information is more detailed than that 
recorded on the CRF. In general, this will include a description of the AE in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of possible 
causality. Information relevant to the event, such as concomitant medications and illnesses must 

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 21 of 29
be provided. In the case of a patient death, a summary of available autopsy findings must be 
submitted as soon as possible to Pfizer or its designated representative. 
9.2. Reporting period 
For each patient, the safety event reporting period begins at the time of the patient's first dose of 
this drug, and lasts through the end of the observation period of the study, which must include at 
least 28 calendar days following the last administration of a drug under study; a report must be 
submitted to Pfizer Safety (or its designated representative) for any of the types of safety events 
listed in the table above occurring during this period. If a patient was administered a drug under 
study on the last day of the observation period, then the reporting period should be extended for 
28 calendar days following the end of observation.
If the investigator becomes aware of a SAE occurring at any time after completion of the study 
and s/he considers the SAE to be related to this drug, the SAE also must be reported to Pfizer 
Safety. 
9.3. Causality assessment
The investigator is required to assess and record the causal relationship. For all AEs, sufficient 
information should be obtained by the investigator to determine the causality of each AE. For 
AEs with a causal relationship to this drug, follow-up by the investigator is required until the 
event and/or its sequelae resolve or stabilize at a level acceptable to the investigator, and Pfizer 
concurs with that assessment.  
An investigator's causality assessment is the determination of whether there exists a reasonable 
possibility that this drug caused or contributed to an AE. If the investigator's final determination 
of causality is "unknown" and s/he cannot determine whether this drug caused the event, the 
safety event must be reported within 24 hours.  
If the investigator cannot determine the etiology of the event but s/he determines that this drug
did not cause the event, this should be clearly documented on the CRF and the NIS AE Report 
Form. 
9.4. Definitions of safety events
9.4.1. Adverse events
An AE is any untoward medical occurrence in a patient administered a medicinal product. The 
event need not necessarily have a causal relationship with this drug treatment or usage. Examples 
of AEs include but are not limited to the following:  

Abnormal test findings (see below for circumstances in which an abnormal test finding 
constitutes an AE);

Clinically significant symptoms and signs;

Changes in physical examination findings;

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 22 of 29

Hypersensitivity;

Progression/worsening of underlying disease;

Lack of efficacy;

Drug abuse;

Drug dependency.
Additionally, for medicinal products, they may include the signs or symptoms resulting from the 
following:

Drug overdose;

Drug withdrawal;

Drug misuse; 

Off-label use; 

Drug interactions;

Extravasation;

EDP;

Exposure during breast feeding;

Medication error;

Occupational exposure.
Abnormal test findings
The criteria for determining whether an abnormal objective test finding should be reported as an 
AE are as follows: 

Test result is associated with accompanying symptoms, and/or

Test result requires additional diagnostic testing or medical/surgical intervention, and/or

Test result leads to a change in study dosing or discontinuation from the study, significant 
additional concomitant drug treatment, or other therapy, and/or

Test result is considered to be an AE by the investigator or Sponsor.

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 23 of 29
Merely repeating an abnormal test, in the absence of any of the above conditions, does not 
constitute an AE. Any abnormal test result that is determined to be an error does not require 
reporting as an AE.
9.4.2. Serious adverse events
A SAE is any untoward medical occurrence in a patient administered a medicinal or nutritional 
product (including pediatric formulas) at any dose that:

Results in death;

Is life-threatening;

Requires inpatient hospitalization or prolongation of hospitalization (see below for 
circumstances that do not constitute AEs);

Results in persistent or significant disability/incapacity (substantial disruption of the ability 
to conduct normal life functions);

Results in congenital anomaly/birth defect.
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event. An important medical event may not be immediately life-threatening and/or result 
in death or hospitalization. However, if it is determined that the event may jeopardize the patient 
or may require intervention to prevent one of the other outcomes listed in the definition above, 
the important medical event should be reported as serious.
Examples of such events are intensive treatment in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or 
development of drug dependency or drug abuse.
Additionally, any suspected transmission via a Pfizer product of an infectious agent, pathogenic 
or non-pathogenic, is considered serious. The event may be suspected from clinical symptoms or 
laboratory findings indicating an infection in a patient exposed to a Pfizer product. The terms 
"suspected transmission" and "transmission" are considered synonymous. These cases are 
considered unexpected and handled as serious expedited cases by PV personnel. Such cases are 
also considered for reporting as product defects, if appropriate.
Hospitalization
Hospitalization is defined as any initial admission (even if less than 24 hours) to a hospital or 
equivalent healthcare facility or any prolongation to an existing admission. Admission also 
includes transfer within the hospital to an acute/intensive care unit (e.g., from the psychiatric 
wing to a medical floor, medical floor to a coronary care unit, neurological floor to a tuberculosis 
unit). An emergency room visit does not necessarily constitute a hospitalization; however, an 
event leading to an emergency room visit should be assessed for medical importance. 

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 24 of 29
Hospitalization in the absence of a medical AE is not in itself an AE and is not reportable. For 
example, the following reports of hospitalization without a medical AE are not to be reported.

Social admission (e.g., patient has no place to sleep)

Administrative admission (e.g., for yearly exam)

Optional admission not associated with a precipitating medical AE (e.g., for elective 
cosmetic surgery)

Hospitalization for observation without a medical AE

Admission for treatment of a pre-existing condition not associated with the development of a 
new AE or with a worsening of the pre-existing condition (e.g., for work-up of persistent 
pre-treatment lab abnormality)

Protocol-specified admission during clinical study (e.g., for a procedure required by the 
study protocol)
9.4.3. Scenarios necessitating reporting to Pfizer Safety within 24 hours 
Scenarios involving EDP, exposure during breastfeeding, medication error, overdose, misuse, 
extravasation, lack of efficacy, and occupational exposure are described below.
EDP
An EDP occurs if:
1.
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed to (e.g., environmental) this drug, or the female becomes, or is found to be, 
pregnant after discontinuing and/or being exposed to this drug (maternal exposure). 
An example of environmental exposure would be a case involving direct contact with a 
Pfizer product in a pregnant woman (e.g., a nurse reports that she is pregnant and has 
been exposed to chemotherapeutic products).
2.
A male has been exposed, either due to treatment or environmental exposure to this drug
prior to or around the time of conception and/or is exposed during the partner pregnancy 
(paternal exposure). 
As a general rule, prospective and retrospective exposures during pregnancy reports from any 
source are reportable irrespective of the presence of an associated AE and the procedures for 
SAE reporting should be followed.
If a study participant or study participant's partner becomes, or is found to be, pregnant during 
the study participant's treatment with this drug, this information must be submitted to Pfizer, 
irrespective of whether an AE has occurred, using the NIS AE Report Form and the EDP 
Supplemental Form. 

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 25 of 29
In addition, the information regarding environmental exposure to this drug, in a pregnant woman 
(e.g., a subject reports that she is pregnant and has been exposed to a cytotoxic product by 
inhalation or spillage) must be submitted using the NIS AE Report Form and the EDP 
Supplemental Form. This must be done irrespective of whether an AE has occurred.  
Information submitted should include the anticipated date of delivery (see below for information 
related to termination of pregnancy).
Follow-up is conducted to obtain general information on the pregnancy, in addition, follow-up is 
conducted to obtain information on EDP outcome for all EDP reports with pregnancy outcome 
unknown. A pregnancy is followed until completion or until pregnancy termination (e.g., 
induced abortion) and Pfizer is notified of the outcome. This information is provided as a follow 
up to the initial EDP report. In the case of a live birth, the structural integrity of the neonate can 
be assessed at the time of birth. In the event of a termination, the reason(s) for termination should 
be specified and, if clinically possible, the structural integrity of the terminated fetus should be 
assessed by gross visual inspection (unless pre-procedure test findings are conclusive for a 
congenital anomaly and the findings are reported).
If the outcome of the pregnancy meets the criteria for a SAE (e.g., ectopic pregnancy, 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly [in a live 
born, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the procedures for 
reporting SAEs should be followed.
Additional information about pregnancy outcomes that are reported as SAEs are as follows: 

Spontaneous abortion includes miscarriage and missed abortion;

Neonatal deaths that occur within 1 month of birth should be reported, without regard to 
causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs 
when the investigator assesses the infant death as related or possibly related to exposure to 
investigational product.
Additional information regarding the EDP may be requested. Further follow-up of birth 
outcomes will be handled on a case-by-case basis (e.g., follow-up on preterm infants to identify 
developmental delays).  
In the case of paternal exposure, the study participant will be provided with the Pregnant Partner 
Release of Information Form to deliver to his partner. It must be documented that the study 
participant was given this letter to provide to his partner.
Exposure during breast feeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of an 
associated AE. An exposure during breastfeeding report is not created when a Pfizer drug 
specifically approved for use in breastfeeding women (e.g., vitamins) is administered in accord 
with authorized use. However, if the infant experiences an AE associated with such a drug's 
administration, the AE is reported together with the exposure during breastfeeding.

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 26 of 29
Medication error
A medication error is any unintentional error in the prescribing, dispensing or administration of a 
medicinal product that may cause or lead to inappropriate medication use or patient harm while 
in the control of the health care professional, patient, or consumer. Such events may be related to 
professional practice, health care products, procedures, and systems including: prescribing; order 
communication; product labeling, packaging, and nomenclature; compounding; dispensing; 
distribution; administration; education; monitoring; and use.
Medication errors include:

Near misses, involving or not involving a patient directly (e.g., inadvertent/erroneous 
administration, which is the accidental use of a product outside of labeling or prescription on 
the part of the healthcare provider or the patient/consumer);

Confusion with regard to invented name (e.g., trade name, brand name).
The investigator must submit the following medication errors to Pfizer, irrespective of the 
presence of an associated AE/SAE:

Medication errors involving patient exposure to this drug, whether or not the medication 
error is accompanied by an AE.

Medication errors that do not involve a patient directly (e.g., potential medication errors or 
near misses). When a medication error does not involve patient exposure to this drug the 
following minimum criteria constitute a medication error report:

An identifiable reporter;

A suspect product;

The event of medication error.
Overdose, misuse, extravasation
Reports of overdose, misuse, and extravasation associated with the use of a Pfizer product are 
reported to Pfizer by the investigator, irrespective of the presence of an associated AE/SAE. 
Lack of efficacy
Reports of lack of efficacy to a Pfizer product are reported to Pfizer by the investigator, 
irrespective of the presence of an associated AE/SAE or the indication for use of the Pfizer 
product.
Occupational exposure
Reports of occupational exposure to a Pfizer product are reported to Pfizer by the investigator, 
irrespective of the presence of an associated AE/SAE.  

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 27 of 29
9.5. Single reference safety document
A Single Reference Safety Document (SRSD) refers to a document that contains the information 
on the known safety profile. The package insert of this drug will be the SRSD in this study. 
Pfizer Japan Inc. will evaluate the safety information reported by the investigator during the 
study period using the SRSD.
The investigator will also prescribe the drug and give the drug administration guidance based on 
the SRSD.
10. PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS
The study results may be published during scientific meetings, in research paper, etc. for the 
purpose of providing proper use information, etc.
COMMUNICATION OF ISSUES
In the event of any prohibition or restriction imposed (e.g., clinical hold) by an applicable 
Competent Authority in any area of the world, or if the investigator is aware of any new 
information which might influence the evaluation of the benefits and risks of a Pfizer product, 
Pfizer should be informed immediately.
In addition, the investigator will inform Pfizer immediately of any urgent safety measures taken 
by the investigator to protect the study patients against any immediate hazard, and of any serious 
breaches of this NI study protocol that the investigator becomes aware of.
11. ORGANIZATIONAL SYSTEM FOR STUDY IMPLEMENTATION
The organizational system in this study is equivalent to that for the operations regarding the post-
marketing study in the RMP. The director of the Post Marketing Study Strategy and 
Management will be responsible for post-marketing study.
12. NAME, ADDRESS AND OUTSOURCED OPERATIONS OF THE PERSON WHO 
WAS CONTRACTED WITH THE OPERATIONS
1)
Contractors 
[1] Operations concerning registration center
Company name: EP-PharmaLine Co.,Ltd.
Address: 3-27-12 Nishi-Ikebukuro, Toshima-ku, Tokyo
[2] Reception of CRF and query form, data management, statistical analysis
Company name: CAC EXICARE Corporation
Address: 24-1 Hakozaki-cho, Nihonbashi, Chuo-ku, Tokyo
2)
Scope of the outsourced operations
Registration center, reception of CRF and query form, data management, and statistical 
analysis (operational jobs excluding the management of the study)

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 28 of 29
13. ADDITIONAL MEASURES THAT MAY BE IMPLEMENTED BASED ON THE 
STUDY RESULTS AND CRITERIA FOR DETERMINATION OF THE INITIATION
The RMP will be reviewed at the planned time of milestone including the followings:

Necessity to change contents of the investigational plan should be discussed with the 
checking presence of new safety specifications. 

Necessity to develop actions to minimize risks for new safety specification should be 
discussed. 

Necessity to revise risk minimization activities for existing safety specifications should be 
discussed. 
14. SCHEDULED TIMING OF MILESTONES AND THEIR RATIONALES FOR 
REPORTING OF STUDY IMPLEMENTATION STATUS AND EVALUATION OF 
OBTAINED RESULTS TO THE PMDA
[Planned time of milestone]
At the time of periodic safety report
[Rationale] 
To review the safety information comprehensively
15. OTHER NECESSARY MATTERS
1) Amendment of the protocol
Based on the new knowledge to be obtained according to the progress of this study, the need for 
amendment of the protocol will be examined and the protocol will be amended if necessary.  
Also, the need for amendment of the protocol will be examined and the protocol will be amended 
even if the partial change in the dosage and administration or indication is approved during the 
reexamination period (except the case when the reexamination period is newly designated), etc.
2) Actions to be taken if any problem or question is observed
In the cases where the onset of any serious and unknown adverse reaction is suggested, a 
significant increase in the frequency of adverse reactions is observed, any problem is found in 
the effectiveness and safety of the drug compared to those prior to the approval, the onset of a 
different kind of adverse reaction is suggested, etc., the amendment of the package insert and 
implementation of a new special investigation or post-marketing clinical study should be 
considered. 

Anaemetro
A6831007 NON-INTERVENTIONAL STUDY PROTOCOL 
Amended1, 10 January 2017
Page 29 of 29
17. REFERENCES
None
18. LIST OF TABLES

Page 10. Table 1. Variables/schedule of observation

Page 13. Table 2. Assessment criteria for [anaerobic infection] / [infectious enterocolitis 
(including pseudomembranous colitis)] 

Page 13. Table 3. Assessment criteria for [amebic dysentery]

Page 14. Table 4. Assessment criteria for microbiological response
19. LIST OF FIGURES
N/A
20. LIST OF STAND ALONE DOCUMENTS
N/A
21. ADDITIONAL INFORMATION
N/A
PPD
PPD